β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS 6974-32-9 Assay ≥99.0% (HPLC) Clofarabine Intermediate High Purity

Name: β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate  CAS: 6974-32-9 Appearance: White or Off-White Crystalline Powder Assay: ≥99.0% (HPLC)  Intermediate of Clofarabine (CAS: 123318-82-1) in the treatment of Children with Acute Lymphoblastic Leukemia (ALL)   Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Commercial Supply Clofarabine Related Intermediates: Clofarabine CAS: 123318-82-1 2-Deoxy-2-fluoro-1,3,5-tri-O-benzoyl-α-D-arabinofuranose CAS: 97614-43-2 β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS: 6974-32-9 1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS: 22224-41-5 2,6-Dichloropurine CAS: 5451-40-1
Item Specifications
Appearance White or Off-White Crystalline Powder
Assay / Analysis Method ≥99.0% (HPLC)
Melting Point 126.0~133.0℃
Loss on Drying ≤0.50%
Residue on Ignition ≤0.50%
Total Impurities ≤1.00%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediate of Clofarabine CAS: 123318-82-1

Description:

Specifications:

Package & Storage:

Chemical Name β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate 
Synonyms 1-O-Acetyl-2,3,5-tri-O-benzoyl-β-D-Ribofuranose
CAS Number 6974-32-9
CAT Number RF-PI222
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C28H24O9
Molecular Weight 504.49
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate (CAS 6974-32-9) is an intermediate of (Clofarabine CAS: 123318-82-1). Clofarabine (CAS: 123318-82-1) is a novel purine nucleoside anticancer drugs is first successfully developed by the Top10 biopharmaceutical company of the United States-Genzyme Corporation with the trade names being “Clofarabine”. On December 28, 2004 the US food and Drug Administration (FDA) used fast-track for approval of clofarabine for application to children with refractory or relapsed acute lymphocytic leukemia (ALL); it has an excellent efficacy on the treatment of leukemia with well tolerance and no unpredictable adverse reactions. It can be administrated through either administered intravenously or administered orally. This drug is the first product approved for being dedicated to the treatment of the children's leukemia in more than ten years.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours